Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA5A | P35218 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL767766 | 0.91 | OPRM1 (0.43) | OPRM1OPRD1CA12CA1CA2 | |
| SCHEMBL768532 | 0.91 | OPRM1 (0.43) | OPRM1OPRD1CA12CA1CA2 | |
| SCHEMBL768952 | 0.90 | OPRM1 (0.44) | OPRM1OPRD1CA12CA1CA2 | |
| SCHEMBL768888 | 0.89 | MCHR1 (0.44) | OPRM1SLC2A1MCHR1 | |
| SCHEMBL769263 | 0.89 | MCHR1 (0.44) | OPRM1SLC2A1MCHR1 | |
| SCHEMBL768639 | 0.89 | OPRD1 (0.44) | OPRM1OPRD1CA12CA1CA2 | |
| SCHEMBL768742 | 0.89 | CA12 (0.40) | OPRM1OPRD1SLC2A1CA12CA1 | |
| Hydrochloric Acid SCHEMBL768804 | 0.88 | OPRD1 (0.43) | OPRM1OPRD1CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL768545 | 0.88 | CHRM4 (0.41) | OPRD1 | |
| SCHEMBL768707 | 0.88 | MCHR1 (0.44) | OPRM1OPRD1SLC2A1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | OPRM1 15/4885OPRD1 56/4885SLC2A1 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.